The latest update is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ).
Hangzhou Tigermed Consulting Co., Ltd. announced its annual results for the year ended December 31, 2024, showing a significant decline in financial performance compared to the previous year. Revenue decreased by 10.6%, gross profit dropped by 21.3%, and net profit attributable to the owners fell by 80%. The company also reported a decrease in total assets and cash equivalents, with a proposed final dividend of RMB3.0 per 10 shares. These results indicate a challenging year for the company, impacting its profitability and financial stability.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the consulting industry. The company provides consulting services, focusing on the healthcare sector, and is listed on the Stock Exchange of Hong Kong Limited.
YTD Price Performance: 7.10%
Average Trading Volume: 65
Technical Sentiment Signal: Hold
Current Market Cap: €5.05B
For an in-depth examination of 3347 stock, go to TipRanks’ Stock Analysis page.